Targeting NK cell inhibitory receptors for precision multiple myeloma immunotherapy
Innate immune surveillance of cancer involves multiple types of immune cells including the
innate lymphoid cells (ILCs). Natural killer (NK) cells are considered the most active ILC …
innate lymphoid cells (ILCs). Natural killer (NK) cells are considered the most active ILC …
PD-L1–PD-1 pathway in the pathophysiology of multiple myeloma
H Tamura, M Ishibashi, M Sunakawa-Kii, K Inokuchi - Cancers, 2020 - mdpi.com
PD-L1 expressed on tumor cells contributes to disease progression with evasion from tumor
immunity. Plasma cells from multiple myeloma (MM) patients expressed higher levels of PD …
immunity. Plasma cells from multiple myeloma (MM) patients expressed higher levels of PD …
Treating multiple myeloma in the context of the bone marrow microenvironment
The treatment landscape of multiple myeloma (MM) has evolved considerably with the FDA-
approval of at least 15 drugs over the past two decades. Together with the use of autologous …
approval of at least 15 drugs over the past two decades. Together with the use of autologous …
Landscape of coordinated immune responses to H1N1 challenge in humans
Influenza is a significant cause of morbidity and mortality worldwide. Here we show changes
in the abundance and activation states of more than 50 immune cell subsets in 35 …
in the abundance and activation states of more than 50 immune cell subsets in 35 …
[HTML][HTML] Regulation of CD38 on multiple myeloma and NK cells by monoclonal antibodies
HT Wu, XY Zhao - International Journal of Biological Sciences, 2022 - ncbi.nlm.nih.gov
CD38 is highly expressed on multiple myeloma (MM) cells and plays a role in regulating
tumor generation and development. CD38 monoclonal antibodies (mAbs) have been used …
tumor generation and development. CD38 monoclonal antibodies (mAbs) have been used …
Resistance mechanisms towards CD38− directed antibody therapy in multiple myeloma
LE Franssen, CAM Stege, S Zweegman… - Journal of Clinical …, 2020 - mdpi.com
Antibodies targeting CD38 are rapidly changing the treatment landscape of multiple
myeloma (MM). CD38− directed antibodies have several mechanisms of action. Fc …
myeloma (MM). CD38− directed antibodies have several mechanisms of action. Fc …
Monoclonal antibodies and antibody drug conjugates in multiple myeloma
J Radocha, NWCJ van de Donk, K Weisel - Cancers, 2021 - mdpi.com
Simple Summary Monoclonal antibodies represent a major therapeutic progress in multiple
myeloma during the last decade. The use of antibodies as well as antibody drug conjugates …
myeloma during the last decade. The use of antibodies as well as antibody drug conjugates …
PD-L1/PD-1 axis in multiple myeloma microenvironment and a possible link with CD38-mediated immune-suppression
F Costa, V Marchica, P Storti, F Malavasi, N Giuliani - Cancers, 2021 - mdpi.com
Simple Summary Despite the impressive clinical impact of programmed death-ligand 1 (PD-
L1)/programmed cell death-1 (PD-1) blockade in solid tumors, the use of these checkpoint …
L1)/programmed cell death-1 (PD-1) blockade in solid tumors, the use of these checkpoint …
[PDF][PDF] Daratumumab 在新诊断不适合移植及复发难治多发性骨髓瘤治疗的Meta 分析
郭怀鹏， 康蕾， 刘聪， 周柰岑， 刘英， 崔栋， 刘利 - 临床血液学杂志, 2021 - lcxy.whuhzzs.com
Daratumumab在新诊断不适合移植及复发难治多发性骨髓瘤治疗的Meta分析 Page 1 2021年
临床血液学杂志 34卷11期 JClinHematol(China) Daratumumab在新诊断不适合移植及复发难治 …
临床血液学杂志 34卷11期 JClinHematol(China) Daratumumab在新诊断不适合移植及复发难治 …
Ocular complications of checkpoint inhibitors and immunotherapeutic agents: a case series
RA Parikh, BC Chaon… - Ocular immunology and …, 2021 - Taylor & Francis
Background: Ophthalmologists have a role in assessing immune-related adverse events
(IRAE) in oncology patients on immunotherapy. We assessed the utility of a hospital-wide …
(IRAE) in oncology patients on immunotherapy. We assessed the utility of a hospital-wide …